分子核医学在嵌合抗原受体T细胞免疫治疗的应用进展  

Advances in application of molecular nuclear medicine in chimeric antigen receptor T cell immunotherapy

作　　者：黄文鹏 杨琦 陈钊 邱永康 宋乐乐 范岩[1] 康磊[1] HUANG Wenpeng;YANG Qi;CHEN Zhao;QIU Yongkang;SONG Lele;FAN Yan;KANG Lei(Department of Nuclear Medicine,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院核医学科,北京100034

出　　处：《中国医学物理学杂志》2023年第9期1057-1063,共7页Chinese Journal of Medical Physics

基　　金：国家自然科学基金(82171970,81871385);北京市杰出青年项目(JQ21025);北大医学青年科技创新发展平台青年培育基金(BMU2022PY006);北京大学临床医学+X青年项目(PKU2021LCXQ023)。

摘　　要：嵌合抗原受体T细胞(CAR-T)疗法作为一种新型、精准靶向的免疫疗法,给血液系统恶性肿瘤的治疗带来了革命性的变化。基于放射性核素的PET、SPECT等分子核医学技术具有非侵入性、长期动态、实时监测活体水平内的分子靶标评价的独特优势,有助于优化输注CAR-T细胞的时机、剂量以及避免潜在的生物毒性,并对指导CAR-T疗法的研发起重要作用。本文对基于放射性核素的分子核医学在CAR-T细胞治疗中的监测和疗效评估应用进行综述,其中一些有前景的分子探针的临床转化有助于监测CAR-T细胞的活性、生物分布和靶向肿瘤部位的传输。Chimeric antigen receptor T cell(CAR-T)therapy as a novel and precision-targeted immunotherapy has revolutionized the treatment of hematologic malignancies.Molecular nuclear medicine technologies such as radionuclidebased PET and SPECT have the unique advantages of non-invasive,long-term dynamic,real-time monitoring of molecular targets at the in vivo level,which are conducive to optimize the timing and dose of CAR-T cell infusion and avoid potential biotoxicity,and play an important role in guiding the development of CAR-T therapy.A review on the application of radionuclide-based molecular nuclear medicine in the monitoring and efficacy assessment of CAR-T therapy is provided.The clinical application of some promising molecular probes helps to monitor CAR-T cell activity,biodistribution and delivery to targeted tumor sites.

关 键 词：分子核医学 免疫疗法 免疫成像 嵌合抗原受体 综述 

分 类 号：R392[医药卫生—免疫学] R811.1[医药卫生—基础医学]